Alzheimer's Association International Conference

September 09, 2021

In addition to his work study pimavanserin in treating dementia-related psychosis, the director of the Banner Alzheimer’s Institute commented on the potential for aducanumab in Alzheimer disease.

September 08, 2021

The director of Banner Alzheimer’s Institute spoke on the importance of biomarkers in Alzheimer disease, as well as the ongoing improvements in digital technologies.

September 07, 2021

Following the COVID-19 pandemic, investigators are seeing a shift towards remote trials in an effort to avoid participants having to be in-person at a brick-and-mortar site.

September 07, 2021

Jacobo Mintzer, MD, MPA, discussed a wide range of Alzheimer disease related topics, including the use of methylphenidate, reactions to AAIC, and the aducanumab approval.

September 03, 2021

The director of the Banner Alzheimer’s Institute discussed areas of success and those facing challenges for Alzheimer disease clinical trials.

September 01, 2021

The global head of Neurodegeneration at Roche/Genentech offered her insights on additional analysis of the DIAN-TU trial of gantenerumab and perspectives on biomarker data.

August 26, 2021

The toolkit’s assays contain several biomarkers, including Aß 1-42, Aß 1-40, α-syn, GFAP, IL-6, neurogranin, NfL, phosphotau181, S100B, sTREM2, total tau, and YKL-40.

August 25, 2021

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the real-world level of dementia education and where it needs improvement.

August 24, 2021

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed employing the MoCA-T app as a means of cognitive screening in rural and ethnically diverse populations.

August 22, 2021

The director of the Center for Brain Health at Miami University Miller School of Medicine discussed how much influence people have on lowering their Alzheimer disease risk.